The stock has a 36-month beta value of -0.16. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AKRO is 71.69M, and at present, short sellers hold a 9.64% of that float. On June 12, 2025, the average trading volume of AKRO was 1.46M shares.
AKRO) stock’s latest price update
Akero Therapeutics Inc (NASDAQ: AKRO)’s stock price has gone decline by -2.87 in comparison to its previous close of 54.52, however, the company has experienced a -0.07% decrease in its stock price over the last five trading days. accessnewswire.com reported 2025-06-08 that NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. (“Akero”or “the Company”) (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/AKRO.
AKRO’s Market Performance
AKRO’s stock has fallen by -0.07% in the past week, with a monthly rise of 27.51% and a quarterly rise of 15.50%. The volatility ratio for the week is 1.71% while the volatility levels for the last 30 days are 5.75% for Akero Therapeutics Inc. The simple moving average for the past 20 days is 10.23% for AKRO’s stock, with a 44.19% simple moving average for the past 200 days.
Analysts’ Opinion of AKRO
Many brokerage firms have already submitted their reports for AKRO stocks, with BofA Securities repeating the rating for AKRO by listing it as a “Buy.” The predicted price for AKRO in the upcoming period, according to BofA Securities is $63 based on the research report published on January 30, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AKRO reach a price target of $72, previously predicting the price at $50. The rating they have provided for AKRO stocks is “Buy” according to the report published on January 27th, 2025.
Citigroup gave a rating of “Buy” to AKRO, setting the target price at $65 in the report published on November 18th of the previous year.
AKRO Trading at 22.64% from the 50-Day Moving Average
After a stumble in the market that brought AKRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.32% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKRO starting from Rolph Timothy, who sale 25,000 shares at the price of $55.04 back on Jun 06 ’25. After this action, Rolph Timothy now owns 169,721 shares of Akero Therapeutics Inc, valued at $1,376,000 using the latest closing price.
Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc, sale 12,500 shares at $53.49 during a trade that took place back on Jun 05 ’25, which means that Rolph Timothy is holding 169,721 shares at $668,634 based on the most recent closing price.
Stock Fundamentals for AKRO
The total capital return value is set at -0.28. Equity return is now at value -27.92, with -26.06 for asset returns.
Based on Akero Therapeutics Inc (AKRO), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -36.91. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -121.42.
Currently, EBITDA for the company is -285.42 million with net debt to EBITDA at 0.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.80.
Conclusion
To sum up, Akero Therapeutics Inc (AKRO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
